Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2018-12-11 Regulatory Filings
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly information regarding the total number of voting rights and total number of shares of the Company' and explicitly references Article 223-16 of the AMF General Regulations. It provides a table detailing the total number of shares and voting rights as of a specific date (November 30, 2018). This type of periodic disclosure regarding share capital and voting rights does not fit neatly into the primary financial report categories (10-K, IR, ER) or specific corporate actions (DIV, SHA, POS). While it relates to capital structure, its primary function is regulatory disclosure of voting power. Given the options, it is a specific regulatory disclosure. Since there is no specific code for 'Voting Rights Disclosure', and it is not a declaration of voting results (DVA) but rather a periodic count, it falls best under the general 'Regulatory Filings' (RNS) as a miscellaneous, mandatory regulatory update, or potentially 'SHA' (Share Issue/Capital Change) due to the mention of total shares, but RNS is a safer fallback for non-standard regulatory updates.
2018-12-11 French
Information relating to the total number of voting rights and shares making up the capital
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly information regarding the total number of voting rights and total number of shares of the Company' and explicitly references Article 223-16 of the AMF General Regulations. It provides a table detailing the total number of shares and voting rights as of a specific date (November 30, 2018). This type of periodic disclosure regarding share capital and voting rights does not fit neatly into the primary financial report categories (10-K, IR, ER) or specific corporate actions (DIV, SHA, POS). While it relates to capital structure, its primary function is regulatory disclosure of voting power. Given the options, it is a specific regulatory disclosure. Since there is no specific code for 'Voting Rights Disclosure', and it is not a declaration of voting results (DVA) but rather a periodic count, it falls best under the general 'Regulatory Filings' (RNS) as a miscellaneous, mandatory regulatory update, or potentially 'SHA' (Share Issue/Capital Change) due to the mention of total shares, but RNS is a safer fallback for non-standard regulatory updates.
2018-12-11 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 90% confidence The document is a press release, dated December 5, 2018, announcing the launch of a pivotal Phase 3 clinical trial (COSMIC-312) by Exelixis and Ipsen regarding the drug cabozantinib for advanced hepatocellular carcinoma (HCC). It details the trial design, objectives (progression-free survival and overall survival), patient population, and collaboration terms. This content is characteristic of a major corporate announcement related to drug development and clinical strategy, which often accompanies or precedes formal regulatory filings or earnings reports. Since it is a detailed announcement about a clinical trial and drug status (including approvals and interactions with regulatory bodies like the FDA and EMA), it is best classified as a general corporate announcement or a specific type of investor communication. Given the options, it is not a standard 10-K, ER, or IR. It is too detailed for a simple RPA or RNS. It is a significant corporate action announcement. While it discusses drug development, it is not a formal Investor Presentation (IP) or a Management Discussion & Analysis (MDA). It is most closely aligned with a general corporate update or a specific regulatory/development update. Since it is a detailed announcement about a clinical trial launch and drug status, and not a formal report itself, the closest fit among the provided codes that captures significant corporate/development news, especially when it involves regulatory context, is often the general Regulatory Filings (RNS) if no better fit exists, or potentially a Capital/Financing Update (CAP) if financing was the main focus (which it is not). However, given the nature of announcing a major clinical trial milestone, it functions as a key piece of investor information. Since it is a press release announcing a major clinical trial, and not a formal financial report, it falls under general corporate communication. In the absence of a specific 'Clinical Trial Announcement' code, RNS (Regulatory Filings/Announcements) serves as the best general category for significant, non-financial-report-specific corporate news releases.
2018-12-05 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release announcing the initiation of a Phase 3 pivotal clinical trial (COSMIC-312) for a drug combination (cabozantinib and atezolizumab) for hepatocellular carcinoma, involving two companies, Exelixis and Ipsen. It details the trial design, endpoints, background on the disease, and safety information for the drug CABOMETYX®. This type of announcement, detailing clinical trial progress and drug information, is characteristic of an Investor Presentation (IP) or a general press release related to R&D/pipeline updates. Since it is a detailed announcement about a specific drug and trial, 'Investor Presentation' (IP) is the most fitting category among the choices, as these often contain detailed clinical/pipeline updates presented to investors, even if formatted as a press release. It is not a formal regulatory filing like 10-K or an earnings release (ER). Given the depth of clinical and safety information, IP is preferred over the general 'RNS'.
2018-12-05 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces a specific corporate event: the dosing of the first patient in a Phase I/II study for a new radionuclide compound (IPN01087) developed by Ipsen and 3BP. This type of announcement, detailing clinical trial progress, partnership updates, and scientific milestones, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing operational/clinical progress rather than a formal financial statement (like 10-K or IR) or a transcript (CT), and it focuses on key operational news, it fits best under the Earnings Release category, which often includes operational highlights alongside or instead of pure financial figures, or as a general Regulatory Filing. Given the focus on a clinical trial milestone, ER is a strong candidate, but since it's not explicitly reporting quarterly/periodical financial results (it's a clinical update), RNS (Regulatory Filings - general/miscellaneous) is the most appropriate fallback for a non-standard operational announcement presented as a press release. However, in many financial databases, significant clinical trial progress announcements are often grouped with ERs if they are material operational news. Given the options, and the fact that it is a formal announcement of a significant development, I will classify it as a general Regulatory Filing (RNS) as it doesn't fit the strict definition of ER (periodical financial results) or any other specific category like M&A or Capital Change. It is a material corporate update.
2018-11-20 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 92% confidence The document is a press release dated November 20, 2018, announcing that Ipsen and 3BP have treated the first patient in a Phase I/II clinical trial for a new radiotherapeutic agent (IPN01087). This type of announcement, detailing clinical trial progress (patient enrollment/treatment initiation) and providing company/product background, is characteristic of an announcement related to research and development progress, often released outside of standard quarterly earnings cycles. It is not a full Annual Report (10-K), an Audit Report (AR), a formal Earnings Release (ER) focusing on financial metrics, or a Call Transcript (CT). Since it details specific R&D progress and partnership milestones, it is best classified as a general corporate announcement that falls under the broad category of Investor Relations material, but given the specific definitions, it most closely aligns with a general regulatory/corporate update that isn't covered by the more specific codes like DIV, CAP, or MANG. However, in the context of financial filings, announcements of clinical trial milestones are often released as press releases that function as material information disclosures. Since there is no specific 'Clinical Trial Update' code, and it is a formal announcement of a significant operational event, it fits best as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but it reads like a press release. Given the options, RNS (Regulatory Filings / miscellaneous announcements) is the most appropriate fallback for a significant, non-financial-results-focused press release detailing operational progress, especially since it is not a formal statutory filing like a 10-K or DEF 14A. The document length (11,797 chars) is substantial, indicating it is the primary content, not just a short announcement of a report (ruling out RPA).
2018-11-20 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.